A follow-on phase 1 trial by Bennett et al. [100] covering 11 patients with childhood-onset blindness caused by RPE65 mutations indicated that one dose of recombinant AAV vector containing the RPE65 gene (AAV2-hRPE65v2) sub-retinally injected into to the contralateral eye in patients enrolled in the phase 1 study, still showed robust safety because of the immune privilege property of the eye. The gene discussed is RPE65; the disease is blindness (disorder).